Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8101379rdf:typepubmed:Citationlld:pubmed
pubmed-article:8101379lifeskim:mentionsumls-concept:C0020944lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C0020259lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:8101379lifeskim:mentionsumls-concept:C0053532lld:lifeskim
pubmed-article:8101379pubmed:issue3lld:pubmed
pubmed-article:8101379pubmed:dateCreated1993-8-19lld:pubmed
pubmed-article:8101379pubmed:abstractTextEffects of chronic treatment with bevantolol, a beta-adrenoceptor blocker, and of repeated immobilization stress on blood pressure, body weight, and [3H]dihydroalprenolol ([3H]DHA) binding to the cerebral cortex were examined in rats. Systolic blood pressure increased to approximately 150 mmHg when stress was applied for 14 days (2 h day-1). This increase was inhibited by chronic treatment with bevantolol (250 mg kg-1 daily). However, bevantolol did not suppress the inhibition of body weight gain by stress. The maximum number of [3H]DHA binding sites (Bmax) in the cerebral cortex was decreased by stress without changing the affinity, and the decrease in Bmax mainly reflected the reduction of beta 1-adrenoceptors. Bevantolol treatment (250 mg kg-1) increased the Bmax to 137% and completely inhibited the downregulation of beta-adrenoceptors by stress. These results show that bevantolol can inhibit both the hypertension and downregulation of the central beta 1-adrenoceptors induced by stress.lld:pubmed
pubmed-article:8101379pubmed:languageenglld:pubmed
pubmed-article:8101379pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:citationSubsetIMlld:pubmed
pubmed-article:8101379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8101379pubmed:statusMEDLINElld:pubmed
pubmed-article:8101379pubmed:monthJullld:pubmed
pubmed-article:8101379pubmed:issn0091-3057lld:pubmed
pubmed-article:8101379pubmed:authorpubmed-author:KigoshiSSlld:pubmed
pubmed-article:8101379pubmed:authorpubmed-author:MuramatsuIIlld:pubmed
pubmed-article:8101379pubmed:authorpubmed-author:TakitaMMlld:pubmed
pubmed-article:8101379pubmed:issnTypePrintlld:pubmed
pubmed-article:8101379pubmed:volume45lld:pubmed
pubmed-article:8101379pubmed:ownerNLMlld:pubmed
pubmed-article:8101379pubmed:authorsCompleteYlld:pubmed
pubmed-article:8101379pubmed:pagination623-7lld:pubmed
pubmed-article:8101379pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:meshHeadingpubmed-meshheading:8101379-...lld:pubmed
pubmed-article:8101379pubmed:year1993lld:pubmed
pubmed-article:8101379pubmed:articleTitleEffects of bevantolol HCl on immobilization stress-induced hypertension and central beta-adrenoceptors in rats.lld:pubmed
pubmed-article:8101379pubmed:affiliationDepartment of Pharmacology, Fukui Medical School, Japan.lld:pubmed
pubmed-article:8101379pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8101379pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed